Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 16/20 | 0.72 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.68 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.68 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.68 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 0.68 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.68 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.68 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.68 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.68 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.68 |
| ▸ | HDAC9 | Q9UKV0 | 4/20 | 0.68 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.68 |
| ▸ | ERBB2 | P04626 | 6/20 | 0.65 |
| ▸ | FBP1 | P09467 | 2/20 | 0.60 |
| ▸ | AURKA | O14965 | 1/20 | 0.60 |
| ▸ | INSR | P06213 | 1/20 | 0.60 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.60 |
| ▸ | FLT4 | P35916 | 1/20 | 0.60 |
| ▸ | KDR | P35968 | 1/20 | 0.60 |
| ▸ | CLK1 | P49759 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7766632 | 0.90 | EGFR (0.57) | EGFRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL4740851 | 0.85 | EGFR (0.66) | EGFRERBB2FBP1RAF1 | |
| SCHEMBL6188789 | 0.84 | EGFR (0.80) | EGFRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL30968994 | 0.82 | EGFR (0.82) | EGFRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL642637 | 0.82 | HDAC3 (0.82) | EGFRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL3328655 | 0.82 | EGFR (0.82) | EGFRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL643972 | 0.82 | HDAC3 (0.67) | EGFRHDAC3HDAC4HDAC1HDAC7 | |
| Hydrochloric Acid SCHEMBL8305110 | 0.82 | EGFR (0.51) | EGFRHDAC3HDAC4HDAC1HDAC7 | |
| Hydrochloric Acid SCHEMBL641764 | 0.82 | EGFR (0.80) | EGFRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL2509266 | 0.82 | EGFR (0.79) | EGFRHDAC3HDAC4HDAC1HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150284340-A1 | QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS INC (US) | 2015-10-08 | — | — | US | disclosed |
| US-20150274678-A1 | QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS INC (US) | 2015-10-01 | — | — | US | disclosed |
| US-9108929-B2 | Quinazoline based EGFR inhibitors | CURIS, INC. (US) | 2015-08-18 | — | — | US | disclosed |
| US-9024024-B2 | Quinazoline based EGFR inhibitors containing a zinc binding moiety | CURIS, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-8975401-B2 | Quinazoline based EGFR inhibitors containing a zinc binding moiety | CURIS, INC. (US) | 2015-03-10 | — | — | US | disclosed |
| EP-2190287-B1 | TARTRATE SALTS OR COMPLEXES OF QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS INC (US) | 2014-10-29 | — | — | EP | disclosed |
| US-8846912-B2 | Tartrate salts of quinazoline based EGFR inhibitors containing a zinc binding moiety | CURIS, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20140221403-A1 | QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140155606-A1 | QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. (US) | 2014-06-05 | — | — | US | disclosed |
| US-20140005391-A1 | QUINAZOLINE BASED EGFR INHIBITORS | CURIS, INC. (US) | 2014-01-02 | — | — | US | disclosed |
| EP-0880507-B1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2005-04-13 | — | — | EP | disclosed |
| US-20030018029-A1 | Quinazoline derivatives | ZENECA LIMITED | 2003-01-23 | — | — | US | disclosed |
| US-6399602-B1 | ANTICANCER AGENTS | ZENECA LIMITED (GB) | 2002-06-04 | — | — | US | disclosed |
| EP-0824525-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-06-13 | — | — | EP | disclosed |
| US-5932574-A | ANTICANCER AGENT | ZENECA LIMITED (GB) | 1999-08-03 | — | — | US | disclosed |
| US-5866572-A | RECEPTOR TYROSINE KINASE INHIBITORY PROPERTIES, TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER. | ZENECA LIMITED (GB) | 1999-02-02 | — | — | US | disclosed |
| EP-0880507-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ZENECA LIMITED (GB) | 1998-12-02 | — | — | EP | disclosed |
| EP-0824525-A1 | QUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1998-02-25 | — | — | EP | disclosed |
| WO-1997030034-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ZENECA LIMITED (GB) | 1997-08-21 | — | — | WO | disclosed |
| WO-1996033977-A1 | QUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1996-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018029-A1 | Quinazoline derivatives | ABL1, FGFR1, ERBB2 | EGFR 25/4885HDAC3 490/4885HDAC4 1630/4885 |
| US-20140221403-A1 | QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | EGFR, HDAC5, ERBB4 | EGFR 1/4885HDAC3 17/4885HDAC4 6/4885 |
| US-20140155606-A1 | QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | EGFR, HDAC1, HDAC5 | EGFR 1/4885HDAC3 19/4885HDAC4 9/4885 |
| US-20140005391-A1 | QUINAZOLINE BASED EGFR INHIBITORS | EGFR, ERBB2, ERBB4 | EGFR 1/4885HDAC3 3479/4885HDAC4 2791/4885 |
| US-20150274678-A1 | QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | EGFR, HDAC1, HDAC5 | EGFR 1/4885HDAC3 19/4885HDAC4 9/4885 |
| US-20150284340-A1 | QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | EGFR, ERBB4, HDAC5 | EGFR 1/4885HDAC3 18/4885HDAC4 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.